Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Demodex Blepharitis

In brief

This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.

Key facts

Study ID

NCT07400965

Run by

Glaukos Corporation

People needed

250

Starts

2025-12-05

Expected to finish

2026-11-01

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signs of Demodex blepharitis in at least one eye
• Best Spectacle Corrected Visual Acuity (BSCVA) of 20/80 Snellen or better in each eye

You may not qualify if…

• Presence of eczema or dermatitis in the ocular region of either eye
• Use of lid hygiene products within 14 days of Screening
• Active ocular infection or inflammation, other than blepharitis, in either eye at Screening
• Women who are pregnant, planning a pregnancy, or nursing
• Have used an investigational drug or device within 30 days prior to Screening or concurrently enrolled in another investigational drug or device trial

Where it is running

• Glaukos Clinical Study Site — Newport Beach, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.